[Pneumococcal pneumonia: epidemiology, therapy, immunoprophylaxis].
Despite modern antibiotic therapies, pneumococcal pneumonia still remains a serious epidemiologic problem. Some 25% of pneumococcal pneumonias are accompanied by bacteremia. The mortality rate in these forms is some 17%, and in patients above 50 it is as high as 28%. Early toxic injury is responsible for the high mortality rate, which is as high as 13,000-60,000 deaths every year in the USA. Several resistant strains of pneumococci have recently been discovered, and for all these reasons research into active immunization against pneumococci has been resumed. A vaccine is now available which consists of polysaccharide antigens of the 14 most important serotypes and confers a protection rate of some 80% against pneumococcal pneumonia. Vaccination is recommended for elderly and debilitated persons in particular.
D000907:Antibodies, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D004917:Erythromycin / Q000627:therapeutic use; D006801:Humans; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000401:mortality*; D018805:Sepsis / Q000209:etiology; D013296:Streptococcus pneumoniae / Q000276:immunology; D013752:Tetracycline
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D010406:Penicillins; D004917:Erythromycin; D013752:Tetracycline
Pneumokokkenpneumonie: Epidemiologie, Therapie, Immunprophylaxe.